Clinical TrialID 5544

ALT-801 DDI Study in Healthy Volunteers

NCT04972396

NASH - Nonalcoholic Steatohepatitis

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
5544
Evidence Id
5544
Core Evidence Id
5544
Source Clinical Trial Id
5527
Herb2 Clinical Trial Id
HBCT005527
Nct Id
NCT04972396
Title
ALT-801 DDI Study in Healthy Volunteers
Status
Completed
Phase
Phase 1
Study Result
No
Study Condition
NASH - Nonalcoholic Steatohepatitis
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER
Intervention
DRUG: ALT-801|DRUG: Metformin|DRUG: Atorvastatin|DRUG: Warfarin|DRUG: Digoxin|DRUG: Ethinylestradiol and Levonorgestrel
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Intervention Purpose
Other
Gender
All
Age
Adult
Enrollment
40
Outcome Measure
Area Under the Plasma Concentration Versus Time Curve (AUC) of metformin and atorvastatin/warfarin and digoxin in presence of steady state ALT-801, Baseline and Day 36|Area Under the Plasma Concentration Versus Time Curve (AUC) of ethinylestradiol and levonorgestrel in presence of steady state ALT-801, Baseline and Day 43
Sponsor Collaborator
Altimmune, Inc.
Funded By
INDUSTRY
Location
Q-Pharm, Herston, Queensland, Australia|CMAX Clinical Research, Adelaide, South Australia, Australia
Other Id
ALT-801-103
Start Date
2021-10-05
Primary Completion Date
2022-05-15
Completion Date
2022-05-15
First Posted
2021-07-22
Results First Posted
Last Update Posted
2022-12-08
Study Document
Study Url
https://clinicaltrials.gov/study/NCT04972396
Title Cn
Title En
ALT-801 DDI Study in Healthy Volunteers
Bilingual Status
semi_complete